About Leucine-rich repeat-containing protein 42
Leucine-rich repeat-containing protein 42 (LRRC42) is a protein
from Homo sapiens identified by UniProt accession
Q9Y546, 428 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Leucine-rich repeat-containing protein 42 |
| UniProt accession | Q9Y546 |
| Gene | LRRC42 |
| Organism | Homo sapiens |
| Length | 428 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (12)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- hormone measurement · score 0.09
- thyroxine measurement · score 0.09
- red blood cell density measurement · score 0.04
- mean corpuscular hemoglobin concentration · score 0.03
- mean corpuscular hemoglobin · score 0.03
- erythrocyte count · score 0.03
- ulcerative colitis · score 0.01
- cancer · score 0.01
- bladder transitional cell carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y546-F1 | alphafold | PREDICTED | 72.56 | — |
Amino-acid sequence (428 residues)
MSYYLSSENH LDPGPIYMRE NGQLHMVNLA LDGVRSSLQK PRPFRLFPKG FSVELCMNRE DDTARKEKTD HFIFTYTREG NLRYSAKSLF SLVLGFISDN VDHIDSLIGF PEQIAEKLFS AAEARQKFTE PGAGLRALQK FTEAYGSLVL CSLCLRNRYL VISEKLEEIK SFRELTCLDL SCCKLGDEHE LLEHLTNEAL SSVTQLHLKD NCLSDAGVRK MTAPVRVMKR GLENLTLLDL SCNPEITDAG IGYLFSFRKL NCLDISGTGL KDIKTVKHKL QTHIGLVHSK VPLKEFDHSN CKTEGWADQI VLQWERVTAE AVKPRETSEP RAAAQRFYGK RSRAEAPLKC PLADTHMNSS EKLQFYKEKA PDCHGPVLKH EAISSQESKK SKKRPFEESE TEQNNSSQPS KQKYVCLAVE DWDLLNSY
Explore Leucine-rich repeat-containing protein 42 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets